Spontaneous pneumomediastinum: An extra muscular manifestation of anti-MDA5 dermatomyositis. Report of 2 cases
The use of specific antibodies in inflammatory myopathies has improved the characterization of this disease, identifying different clinical phenotypes. Patients with dermatomyositis (DM) and anti-MDA5 antibodies display typical skin symptoms, lesser muscular involvement, and a prevalence of intersti...
Saved in:
Published in: | Reumatología clinica (Barcelona) Vol. 20; no. 4; pp. 218 - 222 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
Spain
Elsevier España, S.L.U
01-04-2024
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The use of specific antibodies in inflammatory myopathies has improved the characterization of this disease, identifying different clinical phenotypes. Patients with dermatomyositis (DM) and anti-MDA5 antibodies display typical skin symptoms, lesser muscular involvement, and a prevalence of interstitial lung disease (ILD) of up to 91%. Beyond ILD, spontaneous pneumomediastinum (SN) has been identified as a rare but potentially fatal pulmonary manifestation. Two cases of this complication in patients with anti-MDA5 DM are reported.
El uso de anticuerpos específicos en miopatías inflamatorias ha mejorado la caracterización de esta enfermedad identificando distintos fenotipos clínicos. Los pacientes con dermatomiositis (DM) y anticuerpos anti MDA5 muestran síntomas típicos en piel, menor compromiso muscular y una prevalencia de enfermedad pulmonar intersticial (EPI) de hasta el 91%. Además de la EPI, se ha identificado el neumomediastino espontáneo (NE) como una manifestación pulmonar rara pero potencialmente mortal. Se reportan 2 casos de esta manifestación en pacientes con DM anti MDA5. |
---|---|
Bibliography: | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
ISSN: | 2173-5743 2173-5743 |
DOI: | 10.1016/j.reumae.2024.04.002 |